PDCD1 and melanoma: For all patients in the first‐ and second‐line setting, the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the treatment of metastatic cutaneous melanoma recommend (evidence level: II; recommendation: B) PD‐1‐blocking antibodies, such as pembrolizumab and nivolumab, an anti‐cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) antibody, such as ipilimumab, or BRAF/mitogen‐activated protein kinase kinase (MEK) inhibitor combinations for patients with BRAF‐mutant melanoma when the primary tumor is screened for detection of BRAF V600 mutation.21